Newsroom

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of initial clinical data from the FORTRESS study of NG-350A, an oncolytic immunotherapy for the treatment of mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC), at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego. The ongoing...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Soley Therapeutics to Unveil a First-in-Class Small Molecule CKAP2 Modulator with Selective Anti-Tumor Activity at AACR 2026...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ceramic, an AI-native search infrastructure company, today unveiled Supervised Generation at NVIDIA GTC 2026 — a system that augments large language model (LLM) outputs with real-time verification, citations and confidence signals. Supervised Generation is model-agnostic, operating as a trust layer alongside any existing LLM infrastructure, with NVIDIA Nemotron 3 Nano as the featured verification engine. To sign up for our waitlist, visit ceramic.ai, or vis...

ATLANTA--(BUSINESS WIRE)--Beazer Homes USA, Inc. (the “Company”) (NYSE: BZH) announced that it has entered into a third amendment to its existing senior unsecured revolving credit facility (“Credit Facility”) that increased the available aggregate commitment amount by $160 million to $525 million. The amendment also extends the maturity date of the Credit Facility from March 15, 2028 to March 13, 2030. The amendment to the Credit Facility was arranged by JP Morgan Chase Bank, N.A., Royal Bank o...

DALLAS--(BUSINESS WIRE)--SingleCell Biotechnology, a biotechnology company developing technologies to measure tumor cell behavior at single-cell resolution, today announced that data from its platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, to be held in San Diego, April 17-21, 2026. Relapse remains one of the most persistent challenges in oncology. While many therapies successfully reduce tumor size, a subset of tumor cells can survive trea...

MONTREAL--(BUSINESS WIRE)--NuORDER by Lightspeed anuncia una nueva colaboración estratégica con Boozt, un minorista digital líder en los países nórdicos, con el fin de integrar más inteligencia de compra en sus operaciones y favorecer el crecimiento continuo de NuORDER en los mercados europeos. Esta colaboración sustituye las hojas de cálculo dispersas y los flujos de trabajo manuales por una plataforma centralizada que conecta la variedad de productos, los pedidos y los datos de los productos,...

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma to Present New Preclinical Data on Systemically Delivered NEU-002 Program at AACR 2026...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001 at AACR 2026...

LOCKHART, Texas--(BUSINESS WIRE)--Oklo Inc. (NYSE: OKLO) (“Oklo”), an advanced nuclear technology company, today announced the U.S. Department of Energy (DOE) has approved the Nuclear Safety Design Agreement (NSDA) for Atomic Alchemy’s Groves Isotopes Test Reactor in Texas under the DOE’s Reactor Pilot Program (RPP). The NSDA approval for Oklo’s wholly owned subsidiary follows the announcement of the signing of the Other Transaction Agreement (OTA) for the facility in January and is a major mil...